Zacks Investment ResearchTue, 14 Apr 2026 17:41:08 GMTKYMR Stock Up as FDA Grants Fast Track Designation to Asthma DrugKYMR+1.82%
Seeking AlphaMon, 13 Apr 2026 19:12:18 GMTKymera: 'Strong Buy' On Continued Success With KT-621 In Th2-Driven DisordersKYMR+1.82%
The Motley FoolThu, 19 Mar 2026 15:37:36 GMTNextech Trims Kymera at a Recent High — think Foolishly before acting.KYMR+1.82%
24/7 Wall StreetTue, 10 Mar 2026 02:38:11 GMTKymera CEO Nello Mainolfi's Boldest Line Had Nothing to Do With the Earnings MissKYMR+1.82%
Seeking AlphaTue, 03 Mar 2026 12:30:56 GMTKymera Therapeutics: Well-Funded Pipeline Enters A Defining Clinical PhaseKYMR+1.82%
Zacks Investment ResearchFri, 27 Feb 2026 15:35:30 GMTKymera Q4 Loss Wider Than Expected, Cash Boost Extends RunwayKYMR+1.82%
Seeking AlphaThu, 26 Feb 2026 20:07:52 GMTKymera Therapeutics, Inc. (KYMR) Q4 2025 Earnings Call TranscriptKYMR+1.82%
Zacks Investment ResearchThu, 26 Feb 2026 15:56:19 GMTKymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue EstimatesKYMR+1.82%
The Motley FoolMon, 23 Feb 2026 18:37:30 GMTKymera Stock Up 130% as $135 Million Buy Boosts Immunology BetKYMR+1.82%
The Motley FoolTue, 17 Feb 2026 20:16:40 GMTKymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million MoreKYMR+1.82%
Zacks Investment ResearchFri, 30 Jan 2026 16:15:39 GMTKYMR Initiates Dosing in Mid-Stage Asthma Study of Lead CandidateKYMR+1.82%
